Pacer Advisors Inc. Boosts Stock Position in Jazz Pharmaceuticals PLC $JAZZ

Pacer Advisors Inc. raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 19.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 647,084 shares of the specialty pharmaceutical company’s stock after purchasing an additional 107,144 shares during the period. Pacer Advisors Inc.’s holdings in Jazz Pharmaceuticals were worth $110,004,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cardinal Capital Management grew its position in shares of Jazz Pharmaceuticals by 0.5% during the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock worth $2,471,000 after buying an additional 66 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 9.0% in the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 81 shares during the last quarter. UMB Bank n.a. raised its holdings in Jazz Pharmaceuticals by 12.6% in the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock valued at $123,000 after acquiring an additional 81 shares in the last quarter. Pinnacle Associates Ltd. raised its holdings in Jazz Pharmaceuticals by 0.7% in the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after acquiring an additional 83 shares in the last quarter. Finally, Fairbanks Capital Management Inc. raised its holdings in Jazz Pharmaceuticals by 0.4% in the third quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock valued at $3,298,000 after acquiring an additional 94 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on JAZZ shares. Bank of America raised their price objective on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Raymond James Financial restated an “outperform” rating and issued a $239.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Royal Bank Of Canada increased their price target on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Morgan Stanley reiterated an “overweight” rating and issued a $245.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. Finally, Barclays boosted their price objective on Jazz Pharmaceuticals from $234.00 to $253.00 and gave the company an “overweight” rating in a report on Wednesday, May 27th. Sixteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $246.06.

Insiders Place Their Bets

In related news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the completion of the sale, the director owned 384,682 shares of the company’s stock, valued at $73,281,921. This represents a 1.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Heather Ann Mcsharry sold 2,000 shares of the stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.00, for a total transaction of $482,000.00. Following the sale, the director owned 18,449 shares in the company, valued at approximately $4,446,209. This trade represents a 9.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 13,098 shares of company stock worth $2,832,086. Corporate insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $224.66 on Friday. The company has a market cap of $14.11 billion, a PE ratio of -11,227.39, a P/E/G ratio of 0.20 and a beta of 0.32. The company has a fifty day moving average price of $220.76 and a two-hundred day moving average price of $190.29. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. Jazz Pharmaceuticals PLC has a 12 month low of $105.00 and a 12 month high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The firm had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Research analysts expect that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current year.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz Pharmaceuticals announced a collaboration with AbCellera to discover and develop next-generation T-cell-engaging multispecific antibodies for GI cancers and other solid tumors, a deal that could expand JAZZ’s oncology pipeline and create future licensing or milestone revenue. Article Title
• Positive Sentiment: Multiple reports highlighted the size of the AbCellera agreement, with potential value cited in the hundreds of millions of dollars per program, reinforcing investor interest in Jazz’s ability to use external partnerships to deepen its cancer franchise. Article Title
• Neutral Sentiment: Jazz also shared late-breaking data on Xywav at SLEEP 2026, underscoring continued clinical and commercial support for its neuroscience business, though this update appears less immediate than the AbCellera news. Article Title
• Negative Sentiment: Investors may also note that Director Mark Douglas Smith sold 1,157 shares in a pre-arranged Rule 10b5-1 transaction, which can create a modest negative sentiment signal even though the sale was planned. Article Title

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.